A Benign Medullary Thyroid Cancer

Reza Pishdad 1, Mona Vahidi Rad 2, Lissette Cespedes 3

1. Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University School of Medicine, Baltimore, USA
2. Department of Internal Medicine, McGill University, Montreal, CAN
3. Endocrinology and Metabolism, Rutgers New Jersey Medical School, Newark, USA

Corresponding author: Mona Vahidi Rad, mona.vahidirad@gmail.com

Abstract

Metastatic dissemination occurs in up to 90% of patients with medullary thyroid cancer (MTC) greater than 4 cm in diameter, and elevated calcitonin levels of more than 500 pg/ml preoperatively have been shown to predict the failure to achieve biochemical remission. Herein, we present a patient with a large tumor and extremely elevated calcitonin level, who was subsequently found to show a "benign" behavior with no evidence of metastasis. The relatively benign behavior of this patient's MTC despite its size and extremely elevated calcitonin levels is thought to be suggestive of certain mutation types in MTC to be more associated with better prognostic outcomes. This case report highlights the value of genetic studies on disease prognostication and the need for comprehensive research studies on genomic profiling in MTC to better understand the relationship of different mutations with prognosis and outcome.

Categories: Endocrinology/Diabetes/Metabolism, Internal Medicine

Keywords: fna, cea, calcitonin, nodule, medullary thyroid cancer

Introduction

Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the parafollicular or C cells of the thyroid gland. MTC can be sporadic (75%) or familial (25%) and accounts for about 5% of thyroid cancers. The production of calcitonin is a characteristic feature of this tumor. Metastatic dissemination to both central and latero-cervical lymph nodes occurs in up to 90% of patients with a tumor greater than 4 cm in diameter [1]. Calcitonin level can be used as a prognostic factor and an indicator of remission in MTC. Previous studies have shown that preoperative basal calcitonin level of more than 500 pg/ml is strongly associated with failure to achieve postoperative biochemical remission, which is defined by the failure of serum calcitonin to normalize and postoperative basal or stimulated calcitonin more than 10 pg/ml [2].

Herein, we present a patient with MTC who presented with extremely elevated calcitonin levels and was subsequently found to have a "benign" behaving type of cancer with no evidence of metastasis.

Case Presentation

A 62-year-old woman presented to our endocrinology clinic for evaluation of a two-year history of "lump" sensation in the neck. She reported no dysphagia, choking sensation, neck pain, hoarseness, or any symptoms of hypo/hyperthyroidism. She had no history of radiation to the neck. Physical examination was only remarkable for a 4-cm thyroid nodule on the right side which moved easily with swallowing. No cervical lymphadenopathy was appreciated. Pemberton’s sign was negative. Ultrasound of the neck revealed a right-sided hypoechoic nodule measuring 4.12 x 1.84 cm. The thyroid function test was normal. Calcitonin and carcinoembryonic antigen (CEA) were 8754.0 pg/mL and 29.0 ng/mL, respectively. Fine-needle aspiration (FNA) cytology demonstrated a monomorphic population of numerous spindle cells with very few neoplastic cells that stained focally for Chromogranin A, consistent with MTC (Figures 1, 2).
FIGURE 1: Shows solid sheets of epithelioid cells separated by a delicate fibrovascular stroma.

The cytoplasm is amphophilic. The nuclei are round or oval with a salt and pepper chromatin pattern suggestive of a neuroendocrine origin of the tumor.

FIGURE 2: Shows round nuclei with finely stippled to coarsely clumped chromatin and indistinct nucleoli, which stains positive for amyloid on Congo red staining.

Pan CT revealed no evidence of metastasis. The patient underwent total thyroidectomy after the exclusion of pheochromocytoma. Genetic studies were only remarkable for positive Harvey rat sarcoma viral oncogene homolog (HRAS) mutation. The result for rearranged during transfection (RET) mutation was negative, as
were the results for paired box 8/peroxisome proliferator-activated receptor gamma (PAX8/PPARG),
neuroblastoma RAS viral oncogene homolog (NRAS), and Kirsten rat sarcoma viral oncogene homolog
(KRAS) mutation.

Following surgery, the patient was initiated on Levothyroxine to maintain TSH levels within normal limits.
At 12 months of follow-up, calcitonin level declined to 5 ng/mL, and CEA remained within the normal range
(1.5 ng/mL).

Discussion

MTC is relatively an uncommon type of thyroid malignancy that arises from the neural crest-derived
parafollicular C cells and accounts for approximately 5% or less of thyroid malignancies [3]. The discovery of
MTC necessitates further investigations for evaluation of the disease extent, screening for
pheochromocytoma and hyperparathyroidism, as well as genetic mutation analysis to determine whether
MTC is sporadic or hereditary. Hereditary MTC accounts for about 25% of cases. Sporadic cases of MTC
usually present with a palpable thyroid nodule and may arise clinically at any age with peak incidence during
the fourth and sixth decades of life [1]. Prognostic values in MTC include age at diagnosis, gender, the initial
extent of the disease based on lymph node involvement and distant metastases, vascular invasion, tumor
size, and amyloid staining in tumor tissue. Lymph node metastases are found in up to 90% of MTC patients
with a tumor greater than 4 cm in diameter. Distant metastases are usually diffuse and multiple in involved
organs, including lymph nodes, liver, lungs, bones, and skin [1]. Additionally, measurement of serum
calcitonin and carcinoembryonic antigen (CEA) have prognostic values in MTC. Serum calcitonin level plays
an important role as a predictor for remission, the extent of surgery, and better arrangements for post-
operative follow-up intervals. Calcitonin level above 500 pg/ml was found to have a strong indicative value
for failure to achieve biochemical remission [2,4]. Also, assessment of calcitonin and CEA doubling times
post-operatively provides sensitive markers for progression and aggressiveness of metastatic MTC [5].

MTC is characterized by activating RET proto-oncogene mutations in almost all hereditary cases (multiple
endocrine neoplasia type 2A (MEN2A), multiple endocrine neoplasia type 2B (MEN2B), and familial MTC
syndrome (FMTC)). Germline RET mutations can be indicative of hereditary MTC as well as predicting the
lifetime risk for development of MTC, which can be near to 100% for mutation carriers. These mutations
have been frequently detected in seemingly sporadic cases of MTC, which emphasizes the value of genetic
testing in all MTC patients [6]. About 50% of sporadic cases of MTC have somatic RET mutations. Recent
investigations have shown that 18%-80% of sporadic MTCs which lack somatic RET mutations have somatic
mutations of HRAS, KRAS, and NRAS [7]. RAS mutations in MTC occur most commonly in HRAS (73.9% of
all RAS mutations), followed by KRAS (23.1%) and NRAS (2.9%). These somatic RAS mutations have been
noticed to be mutually exclusive with germline RET mutation, meaning that based on the existing data, if a
somatic RAS mutation is found in association with MTC, then germline RET mutation can be considered
unlikely [8]. Other studies have shown assessment of RAS mutation in sporadic RET-negative MTC can be
valuable for personalized, targeted therapeutic strategies [9]. Reports suggest that MTC patients with HRAS
Q61R mutations had an overall better survival rate and more favorable prognostic outcome [10].

Conclusions

The relatively benign behavior of this patient’s MTC despite the tumor size and significantly elevated
calcitonin and CEA levels highlights the value of the results of genetic studies on disease
prognostication. This case highlights the need for comprehensive research studies on genomic profiling in
MTC to better understand the relationship of different genomic mutations with prognosis and outcome.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In
compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services
info: All authors have declared that no financial support was received from any organization for the
submitted work. Financial relationships: All authors have declared that they have no financial
relationships at present or within the previous three years with any organizations that might have an
interest in the submitted work. Other relationships: All authors have declared that there are no other
relationships or activities that could appear to have influenced the submitted work.

References

1. Leboulleux S, Baudin E, Travagli JP, Schlumberger M: Medullary thyroid carcinoma. Clin Endocrinol (Oxf).
2004, 61:299-310. 10.1111/j.1365-2265.2004.02057.x
2. Machens A, Schneyer U, Holzhause N, Dralle H: Prospects of remission in medullary thyroid carcinoma
according to basal calcitonin level. J Clin Endocrinol Metab. 2005, 90:2029-34. 10.1210/jc.2004-1836
3. Chernock RD, Hagemann IS: Molecular pathology of hereditary and sporadic medullary thyroid carcinomas.
Am J Clin Pathol. 2015, 145:768-77. 10.1093/ajcp/acv077
4. Machens A, Uktat J, Hauptmann S, Dralle H: Abnormal carcinoembryonic antigen levels and medullary

thyroid cancer progression: a multivariate analysis. Arch Surg. 2007, 142:289-93. 10.1001/archsurg.142.3.289

5. Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF: Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005, 90:6077-84. 10.1210/jc.2005-0944

6. Taccaliti A, Silvetti F, Palmonella G, Boscaro M: Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Curr Genomics. 2011, 12:618-25. 10.2174/138920211798120835

7. Wells SA Jr, Asa SL, Dralle H, et al.: Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015, 25:567-610. 10.1089/thy.2014.0335

8. Reagh J, Bullock M, Andrici J, et al.: NRASQ61R mutation-specific immunohistochemistry also identifies the HRASQ61R mutation in medullary thyroid cancer and may have a role in triaging genetic testing for MEN2. Am J Surg Pathol. 2017, 41:75-81. 10.1097/PAS.0000000000000740

9. Moura MM, Cavaco BM, Leite V: RAS proto-oncogene in medullary thyroid carcinoma. Endocr Relat Cancer. 2015, 22:R235-52. 10.1530/ERC-15-0070

10. Spandana B, Gruschkus SK, Waguespack SG, et al.: RAS-mutated sporadic medullary thyroid cancer: A single-center experience. J Clin Oncol. 2020, 38:6584. 10.1200/JCO.2020.38.15_suppl.6584